Sign in

    Sami Corlan

    healthcare analyst at William Blair & Company

    Sami Corwin, Ph.D., is a healthcare analyst at William Blair & Company specializing in biotechnology, with coverage including companies such as Solid Biosciences and Allogene Therapeutics. Corwin has maintained a moderate track record, most recently cited as having a 40.57% success rate on recommendations with an average return of 0.2% per stock, and covers approximately 27 stocks within the biotechnology sector. She joined William Blair in November 2018 after completing her Ph.D. in neuroscience at the University of Illinois–Chicago and a B.S. in biology from UC Irvine. Corwin holds professional credentials relevant to research analysis in the financial sector, contributing expertise on biotech equities through in-depth research reports and targeted investment ratings.

    Sami Corlan's questions to Allogene Therapeutics (ALLO) leadership

    Sami Corlan's questions to Allogene Therapeutics (ALLO) leadership • Q3 2024

    Question

    Brooke on for Sami Corlan asked about the level of physician interest in the ALPHA3 trial and what specific aspects of using cema-cel in the first-line setting—such as community use, affordability, or time to treat—are considered most valuable.

    Answer

    Dr. Zachary Roberts, EVP of R&D and CMO, described physician enthusiasm as 'extremely high,' comparable to the early days of Yescarta's development. He stated that physicians see value in all the mentioned aspects: the ability to use a novel MRD prognostic test, respond immediately with an off-the-shelf therapy, and crucially, provide access to CAR-T treatment in community settings that previously could not offer it.

    Ask Fintool Equity Research AI